|
[1] YOUNOSSI ZM,MARCHESINI G,PINTO-CORTEZ H,et al.Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis:Implications for liver transplantation[J].Transplantation,2019,103(1):22-27.
|
|
[2] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.
|
|
[3] ZHU JZ,ZHOU QY,WANG YM,et al. Prevalence of fatty liver disease and the economy in China:A systematic review[J].World J Gastroenterol,2015,21(18):5695-5706.
|
|
[4] BIJNEN M,JOSEFS T,CUIJPERS I,et al. Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mile[J]. Gut,2018,67(7):1317-1327.
|
|
[5] MRIDHA AR,WREE A,AAB R,et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J]. J Hepatol,2017,66(5):1037-1046.
|
|
[6] IMAJO K,FUJITA K,YONEDA M,et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling[J].Cell Metab,2012,16(1):44-54.
|
|
[7] YAMADA S,KAMADA N,AMIYA T,et al. Gut microbiotamediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis[J]. BMC Gastroenterol,2017,17(1):136.
|
|
[8] GADD VL,SKOIEN R,POWELL EE,et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease[J]. Hepatology,2014,59(4):1393-1405.
|
|
[9] PARK JW,JEONG G,KIM SJ,et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease:Comprehensive study of clinical and immunohistochemical findings in younger Asian patients[J]. J Gastroenterol Hepatol,2007,22(4):491-497.
|
|
[10] TOSELLO-TRAMPONT AC,LANDES SG,NGUYEN V,et al.Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-αproduction[J]. J Biol Chem,2012,287(48):40161-40172.
|
|
[11] SONG M,SCHUSCHKE DA,ZHOU Z,et al. Kupffer cell depletion protects against the steatosis,but not the liver damage,induced by marginal-copper,high-fructose diet in male rats[J]. Am J Physiol Gastrointest Liver Physiol,2015,308(11):g934-g945.
|
|
[12] RENSEN SS,SLAATS Y,NIJHUIS J,et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis[J]. Am J Pathol,2009,175(4):1473-1482.
|
|
[13] JINDAL A,BRUZZI S,SUTTI S,et al. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis(NASH)[J]. Exp Mol Pathol,2015,99(1):155-162.
|
|
[14] STANTON MC,CHEN SC,JACKSON JV,et al. Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice[J]. J Inflamm(Lond),2011,8:8.
|
|
[15] du PLESSIS J,van PELT J,KORF H,et al. Association of adipose tissue inflammation with histological severity of nonalcoholic fatty liver disease[J]. Gastroenterology,2015,149(3):635-648,e14.
|
|
[16] WREE A,EGUCHI A,MCGEOUGH MD,et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis,liver inflammation,and fibrosis in mice[J]. Hepatology,2014,59(3):898-910.
|
|
[17] GONG Z,ZHOU J,ZHAO S,et al. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis[J]. Oncotarget,2016,7(51):83951-83963.
|
|
[18] BÄCKHED F,DING H,WANG T,et al. The gut microbiota as an environmental factor that regulates fat storage[J]. Proc Natl Acad Sci U S A,2004,101(44):15718-15723.
|
|
[19] YE JZ,LI YT,WU WR,et al. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-defcient diet-induced nonalcoholic steatohepatitis[J]. World J Gastroenterol,2018,24(23):2468-2481.
|
|
[20] ROBERT O,BOUJEDIDI H,BIGORGNE A,et al. Decreased expression of the glucocorticoid receptor-GILZ pathway in Kupffer cells promotes liver inflammation in obese mice[J]. J Hepatol,2016,64(4):916-924.
|
|
[21] SVENDSEN P,GRAVERSEN JH,ETZERODT A,et al. Antibody-directed glucocorticoid targeting to CD163 in M2-type macrophages attenuates fructose-induced liver inflammatory changes[J]. Mol Ther Methods Clin Dev,2017,4:50-61.
|
|
[22] LEFEBVRE E,MOYLE G,RESHEF R,et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis[J]. PLo S One,2016,11(6):e0158156.
|
|
[23] KRENKEL O,PUENGEL T,GOVAERE O,et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis[J]. Hepatology,2018,67(4):1270-1283.
|
|
[24] FRIEDMAN SL,RATZIU V,HARRISON SA,et al. A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology,2018,67(5):1754-1767.
|
|
[25] IACOBINI C,MENINI S,RICCI C,et al. Galectin-3 ablation protects mice from diet-induced NASH:A major scavenging role for galectin-3 in liver[J]. J Hepatol,2011,54(5):975-983.
|
|
[26] NOMOTO K,NISHIDA T,NAKANISHI Y,et al. Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease[J]. Sci World J,2012,2012:959824.
|
|
[27] JEFTIC I,JOVICIC N,PANTIC J,et al. Galectin-3 ablation enhances liver steatosis,but attenuates inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis[J]. Mol Med,2015,21:453-465.
|
|
[28] TRRABER PG,ZOMER E. Therapy of experimental NASH and fibrosis with galectin inhibitors[J]. PLo S One,2013,8(12):e83481.
|
|
[29] HARRISON SA,MARRI SR,CHALASANI N,et al. Randomised clinical study:GR-MD-02,a galectin-3 inhibitor,vs.placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis[J]. Aliment Pharmacol Ther,2016,44(11-12):1183-1198.
|
|
[30] YAO J,ZHOU CS,MA X,et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation[J]. World J Gastroenterol,2014,20(39):14430-14441.
|
|
[31] NEUSCHWANDER-TETRI BA,LOOMBA R,SANYAL AJ,et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):A multicentre,randomised,placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.
|
|
[32] YAMAMOTO T,NAKADE Y,YAMAUCHI T,et al. Glucagonlike peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice[J]. World J Gastroenterol,2016,22(8):2512-2523.
|
|
[33] ARMSTRONG MJ,GAUNT P,AITHAL GP,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):A multicentre,double-blind,randomised,placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690.
|
|
[34] ALASFOOR S,ROHM TV,BOSCH AJT,et al. Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver[J]. Sci Rep,2018,8(1):15331.
|
DownLoad: